

| in VIROLOGY  |   |  |  |
|--|---|--|--|
| -  | 7th. European Seminars in Virology (EuSeV) 2019   |  |  |
|  | Program   |  |  |
| FRIDAY 14.06.2019  |   |  |  |
| 13:45-14:00  | Welcome   |  |  |
|  | Dana Wolf, Gabriella Campadelli-Fiume, Thomas Mertens, Michael Kann<br>Giorgio Palù   |  |  |
| Session on Ethical and technological issues about antiviral vaccine and antibodies development Chair: Giorgio Palù |   |  |  |
| 14:00-14:40  | Andrea Grignolio, Cognitive bases for vaccine hesitancy<br>Medical Humanities & Bioethics, Vita-Salute San Raffaele University, Milan, Italy<br>grignolio.andrea@hsr.it   |  |  |
| 14:40-15:20  | Rino Rappuoli, Reverse vaccinology 2.0<br>GSK, Siena, Italy rino.r.rappuoli@gsk.com   |  |  |
| 15:20-16:00  | Melvin Kohn, MSD's Investigational Ebola Vaccine<br>Regional Director of Medical Affairs Lead for Vaccines, MSD. melvin.kohn@msd.com  |  |  |
| 16:00-16:30  | Discussion  |  |  |
| 16:30-17:30  | Selected oral presentations   |  |  |
|  | Matti Sallberg, DNA-based prime-boost active immunotherapy to induce a functional cure in patients with chronic hepatitis B   |  |  |
|  | Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, Laboratory Medicine,<br>Karolinska University Hospital Huddinge, Stockholm   |  |  |
|  | Francesco Santoro, Human transcriptomic response to vaccination with recombinant VSV expressing Ebola virus Glycoprotein  |  |  |
|  | Laboratory of Molecular Microbiology and Biotechnology (LAMMB), Dept. of Medical Biotechnologies, University of Siena, Italy  |  |  |
|  | Matteo Castelli, HCV/E2 dynamics controls overall sensitivity to neutralization<br>Laboratory of Microbiology and Virology, Università "Vita-Salute" San Raffaele, Milan, Italy   |  |  |
|  | Francesco Nicoli, Poor responsiveness of naïve CD8+ T-cells from elderly<br>individuals is associated to their altered basal metabolism Sorbonne<br>Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses (CIMI-<br>Paris), Paris, France - Department of Chemical and Pharmaceutical Sciences, University of<br>Ferrara, Ferrara, Italy<br>Dhanik Reshamwala, Novel anti-virals against Enteroviruses |  |  |
|  | Dhank Reshamwala, Novel anti-vitals against Enterovituses<br>Department of Biological and Environmental Science, Nanoscience Center, University of<br>Jyväskylä, Finland  |  |  |

17:30-18:00

## DISCUSSIONS IN FRONT OF POSTERS

20:00 Dinner

## SATURDAY 15.06.2019

## Regulatory and technological issues about antiviral vaccine and antibodies development

## Chair: Thomas Mertens & Gabriella Campadelli Fiume

| 09:00-09:40 | Guido Silvestri, Towards an HIV vaccine: recent advances from studies in non-human primates   |
|-------------|---|
|             | Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, USA, gsilves@emory.edu   |
| 09:40-10:20 | Christian Sinzger, CMV-Elite-neutralizing Antibodies<br>Institute of Virology, University of Ulm, Ulm, Germany, christian.sinzger@uniklinik-ulm.de  |
| 10:20-11:00 | Gabriella Campadelli Fiume, Oncolytic herpes simplex viruses elicit antigen agnostic vaccine-like anticancer protection Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, |
|             | Bologna, Italy, gabriella.campadelli@unibo.it   |
| 11:00-11:30 | Break   |
| 11:30-12:10 | Thomas Mertens, The art of vaccine recommendations in the real world<br>Institute of Virology, Ulm University Medical Center, Ulm, Germany, thomas.mertens@uni-   |
|             | ulm.de  |
| 12:10-13:30 | Selected oral presentations   |
|             | Alberto Reale, Oncolytic HSV-1 vectors for in situ vaccination against solid tumours  |
|             | Department of Molecular Medicine, University of Padua   |
|             | Greta Forlani, HTLV-1 Tax and HBZ oncoproteins expression and subcellular localization in infection and disease progression: implications for immune-based therapeutic approaches                             |
|             | Laboratories of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Surgery, University of Insubria, Varese, Italy   |
|             | Anna Czarnota, Characterization of anti-hepatitis C neutralizing antibody response after immunization with chimeric hepatitis B/hepatitis C virus like particles.   |
|             | Laboratory of Virus Molecular Biology, Intercollegiate Faculty of Biotechnology of the University of Gdańsk and Medical University of Gdańsk  |
|             | Nir Paran, Antibody Treatment of Smallpox Vaccine Adverse Events  |
|             | Department of Infectious diseases, Israel Institute for Biological Research (IIBR), Ness-Ziona, Israel  |
|             | Carlo De Giuli Morghen, A recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine  |
|             | Catholic University "Our Lady of Good Counsel" Tirana, Albania, Department of Medical Biotechnologies and Translational Medicine, Univ. of Milan, Italy   |
|             | Salomon Ferdinand, An Orf virus-based platform technology for vaccine development using a modulatory brick system   |
|             | University Tuebingen, Interfaculty Institute for Cell Biology, Department for Immunology, Tuebingen, Germany  |
| 13:30-15:00 | Lunch break   |

| Developmer   | Development of vaccines and antibodies against viral infection   |  |  |
|--------------|--|--|--|
| Chair: Dana  | Chair: Dana Wolf   |  |  |
| 15:00-15:40  | Ali Mirazimi, Development of vaccine against Crimean Congo Hemorrhagic<br>Fever; Past and Future<br>Department of Laboratory Medicine, Karolinska University Hospital and KI, Stockholm, Sweden.<br>Ali.Mirazimi@ki.se |  |  |
| 15:40-16:20  | Arnaud Marchant, Maternal and neonatal immunization<br>Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium,<br>arnaud.marchant@ulb.ac.be  |  |  |
| 16:20-17:00  | Frédéric Tangy, Vaccines against Ebolavirus and other emerging viruses<br>Viral Genomics and Vaccination Unit, Institut Pasteur, Paris, France, ftangy@pasteur.fr  |  |  |
| 17:00-17:20  | Break  |  |  |
| 17:20-18:00  | Florian Klein, HIV-Super-neutralizing Antibodies   |  |  |
|              | Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany. florian.klein@uk-koeln.de   |  |  |
| 18:00-19:00  | Selected oral Presentations  |  |  |
|              | Eberhard Hildt, Development of a new vaccine platform for induction of a robust B- and T-cell response against viral infections  |  |  |
|              | Paul-Ehrlich-Institut, Department of Virology, Langen, Germany; German Center for Infection Research (DZIF), Braunschweig  |  |  |
|              | Benjamin Gutjahr, Monoclonal antibodies protect mice in Rift Valley fever<br>challenge model   |  |  |
|              | Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases (INNT),<br>Greifswald – Isle of Riems, Germany  |  |  |
|              | Ola Blixt, Efficient identification of immunodominant (glyco-)peptides for type-<br>specific serology and monoclonal antibody developments   |  |  |
|              | Department of Chemistry, University of Copenhagen, Frederiksberg C, Denmark  |  |  |
|              | Sofia Appelberg, Protection Against Crimean-Congo Hemorrhagic Fever Virus<br>Infection in Mice After Immunization with DNA Plasmids Coding for Different<br>Viral Proteins   |  |  |
|              | Public Health Agency of Sweden, Stockholm  |  |  |
|              | Anna Lucia Tornesello, Humoral immune response to HCV peptides as<br>cancer-progression biomarkers of HCV-infections   |  |  |
|              | Istituto Nazionale Tumori – IRCCS Fondazione Pascale, Naples, Italy  |  |  |
| 20:00 Dinner | r  |  |  |

| SUNDAY 16.06.2019                                    |   |  |
|--|---|--|
| Success and failure of antiviral vaccine development |   |  |
| Chair: Michael Kann                                  |   |  |
| 9:00-9:40  | John J. Skehel, Experimental uses and roles in immunity of antibodies that recognize influenza haemagglutinin |  |
|  | Francis Crick Institute, London, UK, John.Skehel@crick.ac.uk  |  |
| 09:40-10:20  | Emanuele Montomoli, Present and future of anti-influenza vaccinations   |  |
|  | Department of Molecular and Developmental Medicine, University of Siena, Italy,<br>Emanuele.montomoli@unisi   |  |
| 10:20-11:00  | Wolfgang Hammerschmidt, Towards an EBV vaccine  |  |

|                                  | Research Unit Gene Vectors, Helmholtz Zentrum München, Germany, hammerschmidt@helmholtz-muenchen.de               |  |
|----------------------------------|---|--|
| 11:00-11:40                      | Sergio Abrignani, Why is it too difficult to develop a vaccine against HCV INGM, Milan, Italy, abrignani@ingm.org |  |
| 11:40-12:20                      | Giorgio Palù, Clinically and experimentally adopted vaccines against<br>Flavivirus infections and Dengue          |  |
|                                  | Department of Molecular Medicine, University of Padova, Italy, giorgio.palu@unipd.it                              |  |
| 12:20 Closing Remarks and Brunch |   |  |
|                                  |   |  |

.